189 related articles for article (PubMed ID: 17056584)
1. A truncated alternative spliced isoform of human desmoglein 1 contains a specific T cell epitope binding to the pemphigus foliaceus-associated HLA class II DRbeta1*0102 molecule.
Mouquet H; Farci S; Joly P; Maillère B; Leblond J; Drouot L; Leprince J; Tonon MC; Loiseau P; Charron D; Tron F; Gilbert D
J Immunol; 2006 Nov; 177(9):6517-26. PubMed ID: 17056584
[TBL] [Abstract][Full Text] [Related]
2. HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus.
Loiseau P; Lecleach L; Prost C; Lepage V; Busson M; Bastuji-Garin S; Roujeau JC; Charron D
J Autoimmun; 2000 Aug; 15(1):67-73. PubMed ID: 10936030
[TBL] [Abstract][Full Text] [Related]
3. HLA-DRB1 polymorphisms and autoimmune responses to desmogleins in Japanese patients with pemphigus.
Miyagawa S; Amagai M; Niizeki H; Yamashina Y; Kaneshige T; Nishikawa T; Shirai T; Inoko H
Tissue Antigens; 1999 Oct; 54(4):333-40. PubMed ID: 10551416
[TBL] [Abstract][Full Text] [Related]
4. Expression of pemphigus-autoantigen desmoglein 1 in human thymus.
Mouquet H; Berrih-Aknin S; Bismuth J; Joly P; Gilbert D; Tron F
Tissue Antigens; 2008 May; 71(5):464-70. PubMed ID: 18331528
[TBL] [Abstract][Full Text] [Related]
5. T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1.
Lin MS; Swartz SJ; Lopez A; Ding X; Fairley JA; Diaz LA
J Invest Dermatol; 1997 Dec; 109(6):734-7. PubMed ID: 9406813
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells.
Eming R; Hennerici T; Bäcklund J; Feliciani C; Visconti KC; Willenborg S; Wohde J; Holmdahl R; Sønderstrup G; Hertl M
J Immunol; 2014 Nov; 193(9):4391-9. PubMed ID: 25252957
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the regulatory regions in the human desmoglein genes encoding the pemphigus foliaceous and pemphigus vulgaris antigens.
Adams MJ; Reichel MB; King IA; Marsden MD; Greenwood MD; Thirlwell H; Arnemann J; Buxton RS; Ali RR
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):165-74. PubMed ID: 9405290
[TBL] [Abstract][Full Text] [Related]
8. The mapping of linear B-cell epitope regions in the extracellular parts of the desmoglein 1 and 3 proteins: recognition of immobilized peptides by pemphigus patients' serum autoantibodies.
Szabados H; Bősze S; Silló P; Kárpáti S; Hudecz F; Uray K
J Pept Sci; 2013 Feb; 19(2):84-94. PubMed ID: 23297065
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals.
Hertl M; Karr RW; Amagai M; Katz SI
J Invest Dermatol; 1998 Apr; 110(4):388-92. PubMed ID: 9540980
[TBL] [Abstract][Full Text] [Related]
10. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.
Pollmann R; Schmidt T; Eming R; Hertl M
Clin Rev Allergy Immunol; 2018 Feb; 54(1):1-25. PubMed ID: 29313220
[TBL] [Abstract][Full Text] [Related]
11. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus.
Mentink LF; de Jong MC; Kloosterhuis GJ; Zuiderveen J; Jonkman MF; Pas HH
Br J Dermatol; 2007 Apr; 156(4):635-41. PubMed ID: 17263817
[TBL] [Abstract][Full Text] [Related]
13. Epitope analysis of antidesmoglein 1 autoantibodies from patients with pemphigus foliaceus across different activity stages.
Kamiya K; Aoyama Y; Yamasaki O; Kamata A; Yamagami J; Iwatsuki K; Tokura Y
Br J Dermatol; 2016 Jan; 174(1):113-9. PubMed ID: 26294113
[TBL] [Abstract][Full Text] [Related]
14. Pemphigus foliaceus and desmoglein 1 gene polymorphism: is there any relationship?
Petzl-Erler ML; Malheiros D
J Autoimmun; 2005 Sep; 25(2):121-5. PubMed ID: 16242304
[TBL] [Abstract][Full Text] [Related]
15. Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering.
Yoshida K; Ishii K; Shimizu A; Yokouchi M; Amagai M; Shiraishi K; Shirakata Y; Stanley JR; Ishiko A
J Dermatol Sci; 2017 Mar; 85(3):197-207. PubMed ID: 28024684
[TBL] [Abstract][Full Text] [Related]
16. Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1.
Hashimoto T; Amagai M; Garrod DR; Nishikawa T
Epithelial Cell Biol; 1995; 4(2):63-9. PubMed ID: 8688919
[TBL] [Abstract][Full Text] [Related]
17. Relationship between target antigens and major histocompatibility complex (MHC) class II genes in producing two pathogenic antibodies simultaneously.
Zakka LR; Keskin DB; Reche P; Ahmed AR
Clin Exp Immunol; 2010 Nov; 162(2):224-36. PubMed ID: 21069937
[TBL] [Abstract][Full Text] [Related]
18. Identification of a primary antigenic target of epitope spreading in endemic pemphigus foliaceus.
Peng B; Temple BR; Yang J; Geng S; Culton DA; Qian Y
J Autoimmun; 2021 Jan; 116():102561. PubMed ID: 33158670
[TBL] [Abstract][Full Text] [Related]
19. Epistasis between DSG1 and HLA class II genes in pemphigus foliaceus.
Martel P; Gilbert D; Busson M; Loiseau P; Lepage V; Drouot L; Delaporte E; Prost C; Joly P; Charron D; Tron F
Genes Immun; 2002 Jun; 3(4):205-10. PubMed ID: 12058255
[TBL] [Abstract][Full Text] [Related]
20. Immunological hotspots analyzed by docking simulations: evidence for a general mechanism in pemphigus vulgaris pathology and transformation.
Tong JC; Sinha AA
BMC Immunol; 2008 Jun; 9():30. PubMed ID: 18564435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
